Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
171
resultados
Última actualización
13/09/2025 [07:54:00]
Resultados 150 a 171 de 171
Resumen de: CN120349377A
The invention belongs to the technical field of biological medicines, and particularly relates to a wheat peptide with antioxidant stress activity and a preparation method and application thereof. The invention provides a wheat peptide with antioxidant stress activity. The amino acid sequence of the wheat peptide is as shown in SEQ ID NO: 1. The invention discloses a wheat peptide FGWPGPK for protecting oxidative stress nerve cells as well as a screening method and application of the wheat peptide FGWPGPK. A target peptide fragment is identified from wheat germs through enzymolysis and multi-dimensional screening strategies, and it is proved that the target peptide fragment can significantly improve the survival rate of PC-12 cells damaged by H2O2 (72.88%) and reduce the ROS level (125.54%). The peptide fragment has strong antioxidant activity and nerve targeting property, and is suitable for preventing and treating neurodegenerative diseases such as Alzheimer's disease.
Resumen de: CN120324393A
The invention relates to the technical field of medicines, and particularly discloses (2, 4-dichlorophenyl) methyl sulfenyl methane amidine and application of salt thereof. Specifically, the research finds that (2, 4-dichlorophenyl) methyl sulfenyl methane amidine and the available medicinal derivative thereof can obviously enhance memory, improve the survival rate of neuronal cells of a patient or promote the regeneration of neurite of the patient; the compound can be used for preparing medicines and health-care products for treating neurological diseases (such as Alzheimer's disease, vascular dementia or Lewy body dementia).
Resumen de: CN120324440A
The invention discloses application of fosfomycin as a unique active component in preparation of a medicine for preventing and/or treating amyotrophic lateral sclerosis, the chemical formula of fosfomycin is C3H7O4P, and the medicine is used for preventing and/or treating amyotrophic lateral sclerosis with abnormal GGGCC sequence repetition times in a C9orf72 gene. An ALS fruit fly model and a phenotype test thereof prove that the fosfomycin is non-toxic to fruit flies and can weaken the neurodegenerative phenotype of the ALS fruit flies, and the fosfomycin has practical value when being applied to treatment of amyotrophic lateral sclerosis, especially amyotrophic lateral sclerosis with abnormal GGGCC sequence repetition times in a C9orf72 gene.
Resumen de: CN120344513A
The present disclosure provides compounds of Formula I: (I) or an N-oxide thereof or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7 and Z are as described herein; the present disclosure provides processes for preparing such compounds, N-oxides, or salts; intermediates useful for the preparation of such compounds, N-oxides, or salts; the present invention relates to compounds, N-oxides, or salts, and compositions containing such compounds, N-oxides, or salts, and their use for the treatment of M4-mediated (or M4-related) disorders, including, for example, Alzheimer's disease, Parkinson's disease, schizophrenia (e.g., their cognitive and negative symptoms), pain, addiction, and sleep disorders.
Resumen de: CN120324397A
The invention discloses application of Gabapentin in improvement of cognitive impairment of Alzheimer's disease. An application model is an APP/PS1 Alzheimer's disease animal model, a control group is a wild type mouse, Gabapentin granules are dissolved with normal saline and used in an intraperitoneal injection mode, the dosage of single administration is 50 mg/kg, administration is performed for 7 days each month, and then behavioral detection is performed. By detecting and analyzing the actual application result, the effect description of the Gabapentin on the improvement of the AD scene memory is obtained. When the medicine is subjected to intraperitoneal injection and administration, the excessive excitability of neurons can be reduced, the scene memory function of AD mice can be improved, a new use method of Gabapentin is expanded, and a new thought is provided for treatment of AD.
Resumen de: CN120324577A
The invention discloses an application of a natural phagocytosis promoting polypeptide in preparation of a medicine for treating Alzheimer's disease. The polypeptide for promoting natural phagocytosis can be implanted into a cerebrospinal fluid sac through intravenous injection, nasal spray and direct intrathecal injection to treat AD (Alzheimer's disease). The natural phagocytic polypeptide shows a high affinity for A beta and a strong effect in increasing LTP levels of cerebral neurons of old AD mice, conjecturing that this treatment approach can be used to treat AD, rather than just another disease-correcting therapy. The natural phagocytosis promoting polypeptide can be independently used, can also be used in combination with other compounds such as P2X7 antagonists and the like, and has a synergistic treatment effect.
Resumen de: CN120329301A
The invention relates to a lycopodium clavatum alkaloid alpha-obscurine derivative and a pharmaceutical salt thereof, a pharmaceutical composition taking the lycopodium clavatum alkaloid alpha-obscurine derivative as an active component, and application of the lycopodium clavatum alkaloid alpha-obscurine derivative in pharmacy. These compounds, compositions, and their use in the preparation of T-type calcium channel inhibitors, drugs for the treatment or prevention of central or peripheral neurological diseases such as Parkinson's disease, pain, tumors, sleep disorders, epilepsy and the like, or drugs with neuroprotective effects.
Resumen de: CN120329441A
The present disclosure generally relates to immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) that can bind to CD33 protein. The antibodies of the present technology are useful in methods of detecting and treating Alzheimer's disease or CD33-related cancer in a subject in need thereof.
Resumen de: CN120329303A
The invention discloses aloperine derivatives as well as a preparation method and application thereof, and belongs to the technical field of medicine preparation. According to the invention, aloperine is taken as a lead compound, 3, 4-dichlorophenyl-1, 2, 3-triazole is utilized to replace a hydrogen atom at N-12 site of aloperine, and an aloperine derivative A4 is synthesized; the MTT experiment result shows that the nerve cell protection effect of aloperine is enhanced by introducing the 1, 2, 3-triazole fragment, and EC50 of A4 is 4.711 mu M and is obviously stronger than that of aloperine serving as a lead compound and that of donepezil serving as a positive control drug; a Western blot experiment shows that the A4 reduces the relative expression of a p-Tau (Thr 181) protein, a p-P38/P38 protein, a p-ERK1/2/ERK1/2 protein, a p-JNK/JNK protein and a p-NF-kappa B/NF-kappa B protein. The aloperine derivative A4 reduces expression of various inflammatory factors and abnormal phosphorylation of Tau protein by inhibiting an MAPK pathway, so that the aloperine derivative A4 has a high protection effect on nerve cells and has Alzheimer's disease resisting activity.
Resumen de: CN120324328A
The invention discloses an Alzheimer's disease transnasal microneedle drug delivery system and a preparation method thereof, and relates to the technical field of biological medicine, the microneedle drug delivery system comprises a microneedle substrate and a microneedle tip; the microneedle tip comprises a medicine carrying exosome, hyaluronic acid and polyvinylpyrrolidone; the drug-loaded exosome comprises a tobacco leaf exosome, the surface of the tobacco leaf exosome is connected with brain-targeted peptide RVG29, and donepezil is wrapped in the tobacco leaf exosome. The invention further discloses a preparation method of the microneedle drug delivery system. According to the nasal microneedle drug delivery system for Alzheimer's disease, the delivery efficiency of a small molecule drug donepezil to the brain is enhanced, and the nasal microneedle drug delivery system has the advantages of being high in safety, good in curative effect and good in targeting property; the problems that in the prior art, small molecule medicine donepezil difficultly passes through the blood brain barrier and enters the central nervous system, the medicine delivery efficiency is low, the treatment effect is low, and side effects are many are solved.
Resumen de: US2025228868A1
The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: US2025230149A1
The present disclosure provides compositions of (4R,5R)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazo-lidin-2-one (Compound 1). Crystalline and solvate forms of the compound and formulations comprising the compound are also provided. Methods of using the compound and methods of administering the formulations to a subject in need thereof are provided to treat or prevent CNS disorders such as Alzheimer's disease.
Resumen de: WO2025151884A1
The present invention is directed to methods and compositions for the administration of sodium pentosan polysulfate and related glycosaminoglycans, particularly by oral administration, particularly in combination with administration of an intestinal penetration agent. The methods and compositions are suitable for treatment of neurodegenerative diseases such as, but not limited to, Alzheimer's disease. Methods and compositions according to the present invention can be used together with other agents suitable for treatment of neurodegenerative diseases such as, but not limited to, Alzheimer's disease.
Resumen de: WO2025151408A1
Described are Microtubule-associated protein tau (MAPT) antisense oligonucleotides (ASOs) and MAPT ASO conjugates, and methods of using the MAPT ASOs and MAPT ASO conjugates to treat neurodegenerative disorders, such as Alzheimer's disease.
Resumen de: WO2025150507A1
To provide an insulin amyloid polymerized protein, an antibody, antibody-producing B cells and a medical composition capable of effectively preventing and treating Alzheimer type dementia with little side effects. An insulin amyloid polymerized protein is collected from a patient with Alzheimer type dementia to which insulin has been administered for use in the treatment of the patient. An insulin amyloid polymerized protein composition for use in the treatment of a patient with Alzheimer type dementia, wherein an insulin amyloid polymerized protein is obtained by chemically bonding insulin and amyloid. Also provided are an antibody therefor, antibody-producing B cells, and a medical composition.
Resumen de: US2025230206A1
Inhibitors are provided for targeting γ-secretase to reduce amyloid load as a viable strategy in Alzheimer's disease treatment and drug discovery. γ-secretase has been shown to cleave amyloid precursor protein, causing an increase in the extracellular concentration of amyloid-β peptides. This extracellular concentration increase can lead to a build-up of amyloid plaques in patients and associated health complications for them. The inhibitors bind adjacent the transmembrane domain of amyloid precursor protein through both covalent and non-covalent interactions. These interactions inhibit the ability of γ-secretase to cleave the amyloid precursor protein, halting the build-up of extracellular amyloid plaques. The inhibitors exhibit specificity for amyloid precursor proteins, reducing concerns of potential off-target effects.
Resumen de: US2025230172A1
Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Resumen de: GB2637227A
A method of monitoring and treating a subject with ALS based on biomarkers. In some embodiments, the method comprises: identifying that a subject has a ratio of LPS1EGF associated with ALS; and based on the identifying that the subject has the ratio of LPS:EGF associated with ALS, determining that the subject is eligible for sodium chlorite therapy for the ALS, determining based on the ratio of LPS:EGF whether to continue the therapeutic regimen of sodium chlorite; wherein the ratio of LPS:EGF in the subject is no greater than 50 and the therapeutic regimen of sodium chlorite is about 0.2 mg/kg/day to about 3.5 mg/kg/day administered orally and/or parenterally.
Resumen de: WO2024054791A1
The disclosure relates to a combination of active ingredients/adjuvants for the treatment of neurological disorders and diseases such as Alzheimer's disease and mild cognitive impairment (MCI) and memory and cognitive disorders and conditions. In particular, combinations of scyllo-inositol and treatments for Alzheimer's disease such as aducanumab and/or combinations with essential fatty acids such as mixtures of linolenic acid/linoleic acid or vitamin D or vitamin D compounds such as calcifediol are disclosed as useful. The combinations may be in the form of separate dosage forms of each active ingredient or may be an oral dosage form having multiple active ingredients in a single capsule or tablet or oral solution. The invention also relates to a method of treating patients having mild cognitive impairment with MMSE criteria of between 22 to 26 with a pharmaceutically effective amount of scyllo-inositol to treat the disease and to slow down progression to Alzheimer's disease.
Resumen de: CN120310674A
The invention relates to the technical field of biological fermentation, and discloses exosome-like nano-vesicles derived from polygonatum sibiricum fermentation as well as a preparation method and application of the exosome-like nano-vesicles. The preparation method of the exosome-like nano-vesicle comprises the following steps: centrifuging a rhizoma polygonati fermentation liquid, collecting a supernatant, and filtering the supernatant to obtain the exosome-like nano-vesicle. The preparation method of the exosome-like nano vesicle provided by the invention has the advantages that the steps are simple; the obtained exosome-like nano vesicles can well relieve neuron activity reduction induced by neurotoxin MPP +, and have the effects of protecting nerve cells and promoting cell activity; the dyskinesia of the Parkinson's disease mouse model can be weakened, and the cognitive function of the modeling mouse can be recovered; the polypeptide has the potential of being applied to preparation of drugs for preventing and treating neurodegenerative diseases such as Parkinson's disease, does not cause adverse effects on organs such as brain and colon of an organism, and has the characteristics of high biological safety, good stability, high activity, brain targeting and the like.
Nº publicación: CN120305240A 15/07/2025
Solicitante:
XUANWU HOSPITAL CAPITAL MEDICAL UNIV
\u9996\u90FD\u533B\u79D1\u5927\u5B66\u5BA3\u6B66\u533B\u9662
Resumen de: CN120305240A
The invention relates to application of a 4-hydroxymandelic acid compound shown in a formula I in preparation of a medicine for preventing or treating Alzheimer's disease. The 4-hydroxymandelic acid compound is expected to be used for improving the learning and memory ability and cognitive impairment of AD patients, so that the 4-hydroxymandelic acid compound is used for preventing or treating AD or assisting in improving the memory function. # imgabs0 # (I)
BOPI
Sede Electrónica
